Gilead Sciences, Inc.

Cellares became the first company to announce receipt of an Advanced Manufacturing Technology designation from the US FDA on 1 April 2025, almost three years after the FDA Omnibus Reform Act of 2022 c

Glucagon-like peptide-1 (GLP-1) receptor agonists, particularly Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), have made a significant difference for patients with obesity

The biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell

Industry anxiety is riding high as pharmaceutical manufacturers wait to hear from US president Donald Trump about whether or not drugs will be included in the next round of tariffs to be announced on